Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells

Renate L Lamprecht; Paul Kennedy; Suzanne M Huddy; Susanne Bethke; Megan Hendrikse; Inga I Hitzeroth; Edward P Rybicki

doi:10.1038/srep20431

journal article Open Access Feb 08, 2016

Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells

Renate L Lamprecht Paul Kennedy Suzanne M Huddy Susanne Bethke Megan Hendrikse Inga I Hitzeroth Edward P Rybicki

Scientific Reports Vol. 6 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/srep20431

Abstract

AbstractHuman papillomaviruses (HPV) cause cervical cancer and have recently also been implicated in mouth, laryngeal and anogenital cancers. There are three commercially available prophylactic vaccines that show good efficacy; however, efforts to develop second-generation vaccines that are more affordable, stable and elicit a wider spectrum of cross-neutralising immunity are still ongoing. Testing antisera elicited by current and candidate HPV vaccines for neutralizing antibodies is done using a HPV pseudovirion (PsV)-based neutralisation assay (PBNA). PsVs are produced by transfection of mammalian cell cultures with plasmids expressing L1 and L2 capsid proteins and a reporter gene plasmid, a highly expensive process. We investigated making HPV-16 PsVs in plants, in order to develop a cheaper alternative. The secreted embryonic alkaline phosphatase (SEAP) reporter gene and promoter were cloned into a geminivirus-derived plant expression vector, in order to produce circular dsDNA replicons. This was co-introduced into Nicotiana benthamiana plants with vectors expressing L1 and L2 via agroinfiltration and presumptive PsVs were purified. The PsVs contained DNA and could be successfully used for PBNA with anti-HPV antibodies. This is the first demonstration of the production of mammalian pseudovirions in plants and the first demonstration of the potential of plants to make DNA vaccines.

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

HPV: The global burden

James Mitchell Crow

Nature 2012 10.1038/488s2a

[2]

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Jan M. M. Walboomers, Marcel V. Jacobs, M. Michele Manos et al.

The Journal of Pathology 1999 10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f

[3]

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

Nubia Muñoz, F. Xavier Bosch, Silvia de Sanjose et al.

New England Journal of Medicine 2003 10.1056/nejmoa021641

[4]

Buck, C. B. et al. Arrangement of L2 within the papillomavirus capsid. J Virol 82, 5190–5197 (2008). 10.1128/jvi.02726-07

[5]

Holmgren, S. C., Patterson, N. A., Ozbun, M. A. & Lambert, P. F. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol 79, 3938–3948 (2005). 10.1128/jvi.79.7.3938-3948.2005

[6]

Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. & Schiller, J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences 89, 12180–12184 (1992). 10.1073/pnas.89.24.12180

[7]

Wang, J. W. & Roden, R. B. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines 12, 129–141 (2013). 10.1586/erv.12.151

[8]

Barksdale, S. & Baker, C. C. Differentiation-specific expression from the bovine papillomavirus type 1 P2443 and late promoters. J Virol 67, 5605–5616 (1993). 10.1128/jvi.67.9.5605-5616.1993

[9]

Conway, M. J. & Meyers, C. Replication and Assembly of Human Papillomaviruses. Journal of Dental Research 88, 307–317 (2009). 10.1177/0022034509333446

[10]

Pastrana, D. V. et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216 (2004). 10.1016/j.virol.2003.12.027

[11]

Buck, C. B., Pastrana, D. V., Lowy, D. R. & Schiller, J. T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods in molecular medicine 119, 445–462 (2005).

[12]

Rybicki, E. P. Plant-produced vaccines: promise and reality. Drug discovery today 14, 16–24 (2009). 10.1016/j.drudis.2008.10.002

[13]

Rybicki, E. P. Plant-made vaccines for humans and animals. Plant biotechnology journal 8, 620–637 (2010). 10.1111/j.1467-7652.2010.00507.x

[14]

Schillberg, S., Twyman, R. M. & Fischer, R. Opportunities for recombinant antigen and antibody expression in transgenic plants-technology assessment. Vaccine 23, 1764–1769 (2005). 10.1016/j.vaccine.2004.11.002

[15]

Tiwari, S., Verma, P. C., Singh, P. K. & Tuli, R. Plants as bioreactors for the production of vaccine antigens. Biotechnology advances 27, 449–467 (2009). 10.1016/j.biotechadv.2009.03.006

[16]

D’Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant biotechnology journal 8, 607–619 (2010). 10.1111/j.1467-7652.2009.00496.x

[17]

Thuenemann, E. C., Meyers, A. E., Verwey, J., Rybicki, E. P. & Lomonossoff, G. P. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant biotechnology journal 11, 839–846 (2013). 10.1111/pbi.12076

[18]

Biemelt, S., Sonnewald, U., Galmbacher, P., Willmitzer, L. & Muller, M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 77, 9211–9220 (2003). 10.1128/jvi.77.17.9211-9220.2003

[19]

Kohl, T. O., Hitzeroth, I. I., Christensen, N. D. & Rybicki, E. P. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC biotechnology 7, 56 (2007). 10.1186/1472-6750-7-56

[20]

Maclean, J. et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 88, 1460–1469 (2007). 10.1099/vir.0.82718-0

[21]

Matic, S. et al. Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods. Plant biotechnology journal 10, 410–421 (2012). 10.1111/j.1467-7652.2011.00671.x

[22]

Varsani, A. et al. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77, 8386–8393 (2003). 10.1128/jvi.77.15.8386-8393.2003

[23]

Warzecha, H. et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77, 8702–8711 (2003). 10.1128/jvi.77.16.8702-8711.2003

[24]

Pereira, R., Hitzeroth, I. I. & Rybicki,E. P. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol 154, 187–197 (2009). 10.1007/s00705-009-0310-3

[25]

Regnard, G. L., Halley-Stott, R. P., Tanzer, F. L., Hitzeroth, I. I. & Rybicki,E. P. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant biotechnology journal 8, 38–46 (2010). 10.1111/j.1467-7652.2009.00462.x

[26]

Rybicki, E. P. & Martin, D. P. Virus-Derived ssDNA Vectors for the Expression of Foreign Proteins in Plants. Current topics in microbiology and immunology 375, 19–45 (2014).

[27]

Huang, Z., Chen, Q., Hjelm, B., Arntzen, C. & Mason, H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnology and bioengineering 103, 706–714 (2009). 10.1002/bit.22299

[28]

Zhang, X. & Mason, H. Bean yellow dwarf virus replicons for high‐level transgene expression in transgenic plants and cell cultures. Biotechnology and bioengineering 93, 271–279 (2006). 10.1002/bit.20695

[29]

Yeager, M. D. et al. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278, 570–577 (2000). 10.1006/viro.2000.0674

[30]

Peng, S. et al. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther 17, 1453–1464 (2010). 10.1038/gt.2010.106

[31]

Peng, S., Ma, B., Chen, S. H., Hung, C. F. & Wu, T. DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci 1, 26 (2011). 10.1186/2045-3701-1-26

[32]

Gordon, S. N. et al. Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol 188, 714–723 (2012). 10.4049/jimmunol.1101404

[33]

Touze, A. & Coursaget, P. In vitro gene transfer using human papillomavirus-like particles. Nucleic acids res 26, 1317–1323 (1998). 10.1093/nar/26.5.1317

[34]

Ma, B., Roden, R. B., Hung, C. F. & Wu, T. C. HPV pseudovirions as DNA delivery vehicles. Therapeutic delivery 2, 427–430 (2011). 10.4155/tde.11.28

[35]

Okun, M. M. et al. L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol 75, 4332–4342 (2001). 10.1128/jvi.75.9.4332-4342.2001

[36]

Stauffer, Y., Raj, K., Masternak, K. & Beard, P. Infectious human papillomavirus type 18 pseudovirions. Journal of molecular biology 283, 529–536 (1998). 10.1006/jmbi.1998.2113

[37]

Buck, C. B., Pastrana, D. V., Lowy, D. R. & Schiller, J. T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78, 751–757 (2004). 10.1128/jvi.78.2.751-757.2004

[38]

Rossi, J. L., Gissmann, L., Jansen, K. & Muller, M. Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae. Hum Gene Ther 11, 1165–1176 (2000). 10.1089/10430340050015211

[39]

Unckell, F., Streeck, R. E. & Sapp, M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71, 2934–2939 (1997). 10.1128/jvi.71.4.2934-2939.1997

[40]

White, W. I. et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73, 4882–4889 (1999). 10.1128/jvi.73.6.4882-4889.1999

[41]

Day, P. M. et al. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 81, 8784–8792 (2007). 10.1128/jvi.00552-07

[42]

Catrice, E. V. & Sainsbury, F. Assembly and Purification of Polyomavirus-Like Particles from Plants. Mol Biotechnol 57, 904–913 (2015). 10.1007/s12033-015-9879-9

[43]

Rybicki, E. P. Plant-based vaccines against viruses. Virol J 11, 205 (2014). 10.1186/s12985-014-0205-0

Metrics

25

Citations

43

References

Details

Published: Feb 08, 2016
Vol/Issue: 6(1)
License: View

Authors

Cite This Article

Renate L Lamprecht, Paul Kennedy, Suzanne M Huddy, et al. (2016). Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells. Scientific Reports, 6(1). https://doi.org/10.1038/srep20431

Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells

You May Also Like